| Literature DB >> 26179020 |
Ognjen Sekulovic1, Maicol Ospina Bedoya1, Amanda S Fivian-Hughes2, Neil F Fairweather2, Louis-Charles Fortier1.
Abstract
Bacteriophages are present in virtually all ecosystems, and bacteria have developed multiple antiphage strategies to counter their attacks. Clostridium difficile is an important pathogen causing severe intestinal infections in humans and animals. Here we show that the conserved cell-surface protein CwpV provides antiphage protection in C. difficile. This protein, for which the expression is phase-variable, is classified into five types, each differing in their repeat-containing C-terminal domain. When expressed constitutively from a plasmid or the chromosome of locked 'ON' cells of C. difficile R20291, CwpV conferred antiphage protection. Differences in the level of phage protection were observed depending on the phage morphological group, siphophages being the most sensitive with efficiency of plaquing (EOP) values of < 5 × 10(-7) for phages ϕCD38-2, ϕCD111 and ϕCD146. Protection against the myophages ϕMMP01 and ϕCD52 was weaker, with EOP values between 9.0 × 10(-3) and 1.1 × 10(-1). The C-terminal domain of CwpV carries the antiphage activity and its deletion, or part of it, significantly reduced the antiphage protection. CwpV does not affect phage adsorption, but phage DNA replication is prevented, suggesting a mechanism reminiscent of superinfection exclusion systems normally encoded on prophages. CwpV thus represents a novel ubiquitous host-encoded and phase-variable antiphage system in C. difficile.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26179020 PMCID: PMC4737114 DOI: 10.1111/mmi.13121
Source DB: PubMed Journal: Mol Microbiol ISSN: 0950-382X Impact factor: 3.501
List of bacterial strains, plasmids and phages used in this study
| Strain, plasmid or phage | Characteristic or description | Reference or source |
|---|---|---|
|
| ||
| R20291 | Epidemic isolate, ribotype 027 | Stabler |
| R20291OFF | R20291 Cd1004‐144a::CT, | Sekulovic and Fortier ( |
| R20291OFFlysogen | R20291OFF strain, carrying the ϕCD38‐2 prophage | This study |
| R20291ON | R20291 Cd1004‐144a::CT, | This study |
| R20291ONlysogen | R20291ON strain, carrying the ϕCD38‐2 prophage | This study |
| R20291OFF( | R20291OFF containing pCBR080, | This study |
| R20291OFF( | R20291OFF containing pCBR106, | This study |
| R20291OFF( | R20291OFF containing pCBR107, | This study |
| R20291OFF( | R20291OFF containing pCBR109, | This study |
| R20291OFF( | R20291OFF containing pOS200, | This study |
| R20291OFF( | R20291OFF containing pOS201, | This study |
| R20291OFF( | R20291OFF containing pOS202, | This study |
| R20291OFF( | R20291OFF containing pOS203, | This study |
| CD384 | Human isolate | Sirard |
| CD384(pRPF144E) | CD384 containing pRPF144E | This study |
| CD384( | CD384 containing pCBR080, | This study |
| CD384( | CD384 containing pCBR106, | This study |
| CD384( | CD384 containing pCBR109, | This study |
|
| ||
| CA434 | HB101 carrying plasmid R702 | Purdy |
| Phage | ||
| ϕCD38‐2 |
| Sekulovic |
| ϕCD111 |
| Sekulovic |
| ϕCD146 |
| Sekulovic |
| ϕMMP01 |
| Meessen‐Pinard |
| ϕCD52 |
| Fortier and Moineau ( |
| Plasmid | ||
| pRPF144 |
| Fagan and Fairweather ( |
| pRPF144E | pRPF144 without | This study |
| pCBR080 | pMTL960 containing the full‐length | Reynolds |
| pCBR106 | pMTL960 containing the full‐length | Reynolds |
| pCBR107 | pMTL960 containing the full‐length | Reynolds |
| pCBR109 | pMTL960 containing the full‐length | Reynolds |
| pOS200 | pRPF144 containing the full‐length | This study |
| pOS201 | pRPF144 containing the N‐terminal domain of the | This study |
| pOS202 | pRPF144 containing the N‐terminal domain + 3 proximal repeats of the | This study |
| pOS203 | pRPF144 containing the | This study |
Figure 1Susceptibility of . difficile to phage infection in spot‐test assays. Bacterial lawns were prepared with the wild‐type R20291, or the R20291OFF mutant strain, carrying (+) or not (−) the pOS200 plasmid expressing the cwp type II. A 5 μl drop containing different titers of the phages ϕCD38‐2, ϕCD111 or ϕCD146 were then deposited on top of the lawns. Zones of clearing after incubation denote susceptibility to phage infection. The assay has been repeated at least three times and a representative result is shown.
Figure 2Bacterial survival following infection with phage ϕCD38‐2. Bacteria were infected with phage ϕCD38‐2 at a MOI of 1, and were subsequently plated after 15 minutes of incubation. The R20291ON (locked ‘ON’) and R20291OFF (locked ‘OFF’) strains were compared with the wild‐type R20291. Plasmids carrying either the full‐length cwp ‐II (pOS200), a truncated version with only the N‐terminal portion (pOS201) or a partially truncated version lacking the distal 5 repeats (pOS202) were also tested in R20291OFF. Colonies representing bacteria that survived the infection were counted and the result is expressed as a percentage of the ratio between infected and uninfected controls. Vertical bars represent means ± standard deviation (SD) of three independent biological replicates, which were each plated in technical triplicates. One‐way ANOVA comparisons were done with R20291OFF as the reference condition (**P < 0.01; ****P < 0.0001).
Figure 3Schematic representation of the CwpV constructions used in this study. The type of CwpV is indicated on the left, along with the strain from which it originates, and the plasmid carrying a copy of the corresponding gene used for expression assays in R20291OFF. Color code: Black, signal peptide; gray, cell wall‐anchoring domain (PF04122); white, unknown function; pink, serine/glycine‐rich region; blue, type I repeats; orange, type II repeats; green, type III repeats; red, type IV repeats, purple, type V repeats. Color shades represent different sequence variants of a repeat type. Constructions marked with asterisks are not naturally occurring. Modified from (Reynolds et al., 2011).
Efficiency of plaquing (EOP) for morphologically different phages infecting strains expressing various types of CwpV
| CwpV type |
|
| |||
|---|---|---|---|---|---|
| ϕCD38‐2 | ϕCD111 | ϕCD146 | ϕMMP01 | ϕCD52 | |
| I | < 5 × 10−7 | < 5 × 10−7 | < 5 × 10−7 | 9 × 10−3 | 1.5 × 10−2 |
| II | < 5 × 10−7 | < 5 × 10−7 | < 5 × 10−7 | ND | ND |
| III | < 5 × 10−7 | < 5 × 10−7 | < 5 × 10−7 | 5.6 × 10−2 | 3.3 × 10−2 |
| IV | < 5 × 10−7 | < 5 × 10−7 | < 5 × 10−7 | ND | ND |
| V | < 5 × 10−7 | < 5 × 10−7 | < 5 × 10−7 | 9.7 × 10−2 | 1.1 × 10−1 |
ND = not determined.
CwpV is a cell wall–associated protein conserved across the Clostridium difficile species. An epigenetic switch controls the expression of the cwpV gene in a phase‐variable manner. Bacterial cells that are in the « ON » state express cwpV and become resistant to phage infection through blocking of phage DNA injection, in a manner reminiscent of superinfection exclusion systems. CwpV thus represents a novel antiphage system conserved in C. difficile.
Figure 4Phage adsorption assay of ϕCD38‐2 on strains expressing or not the type II CwpV. Phages were allowed to adsorb for 30 minute, and then bacteria were pelleted. The adsorption rate is expressed as a percentage of the ratio between non‐adsorbed phages in the supernatant compared to the initial phage inoculum. Vertical bars represent means ± SD of three independent biological replicates, which were also plated in technical triplicates. One‐way ANOVA comparisons were done with R20291OFF as the reference strain (*P < 0.05).
Figure 5Phage DNA replication assay. The R20291OFF and R20291OFF strain carrying the pOS200 plasmid enabling overexpression of the type II CwpV were each infected with ϕCD38‐2 at a MOI of 1. Samples of the infected cultures were collected at different time points post‐infection, and whole bacterial genomic DNA was extracted. DNA was digested with HindIII and analysed by agarose gel and ethidium bromide staining (upper panel). Southern blot hybridization using a Dig‐labeled whole phage DNA probe was then performed to detect phage DNA replication (lower panel). A non‐infected (NI) control was run in parallel, along with a positive control consisting in the purified ϕCD38‐2 DNA.